Bluebird Bio, INC.

Based in MA

🤖

AI Overview

With $3.5M in lobbying spend across 29 quarterly filings, Bluebird Bio, INC is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2019 to 2024.

$3.5M
Total Spend
6
Years Active
1
Firms Hired
5
Lobbyists Deployed
3
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2019$570K
2020$780K
2021$760K
2022$140K
2023$830K
2024$390K

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Bluebird Bio, INC. disclosed contacting in their lobbying filings.

Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESSENATEOffice of Management & Budget (OMB)Centers For Medicare and Medicaid Services (CMS)White House Office
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Pharmacy, Health Issues

Alternative payment models related to novel therapies.

Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability Value and Efficiency Act.

Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing and other issues that impact the industry generally, and bluebird b

S. 2543, Prescription Drug Pricing Reduction Act: issues related to value-based payment.

Issues related to value-based drug pricing and drug pricing in general.

Issues related to H.R. 2507, Newborn Sc

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.